Novartis to Buy Majority Stake in China's Zhejiang Tianyuan Bio-Pharmaceutical Company

Wed, 11/04/2009 - 3:41am
BASEL, Switzerland (AP) — Novartis AG said Wednesday it is paying $125 million for an 85 percent stake in Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd. Privately-held Tianyuan sells vaccines against diseases such as hemorrhagic fever with renal syndrome, or HFRS, caused by hantaviruses, and conducts research into "various preventable viral and bacterial diseases," Novartis said. The Chinese company had net sales of $25 million in 2008. The deal, which requires regulatory approval, comes a day after Novartis announced it will invest some $1.25 billion in its research centers in China over the next five years.

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.